Business Wire

Promega Launches Paradyme™ 27GY STR System, Minimizing Stutter Artifacts in Forensic DNA Analysis

29.9.2026 13:00:00 CEST | Business Wire | Press Release

Share

Promega Corporation has launched Paradyme™ 27GY STR System, the first commercially available short tandem repeat (STR) analysis kit to include the company’s Reduced-Stutter Polymerase (RSP). This novel enzyme, engineered by Promega, significantly reduces the most common type of confounding artifact in forensic DNA analysis. The result is an 8-fold reduction in stutter signal intensity, producing clearer electropherograms, improving confidence in number-of-contributors (NoC) determination, and enhancing detection of minor contributors in mixed samples. Ultimately, this leads to faster mixture interpretation with higher confidence and the ability to interpret more complex mixtures, helping labs solve more cases and reduce backlogs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918993802/en/

“This is the first forensic STR analysis kit to virtually eliminate stutter at its source,” says Tim Kupferschmid, Sr. Director of Genetic Identity, Promega Corporation. “By simplifying mixture deconvolution, Paradyme™ 27GY STR System will fundamentally change what analysts can deliver to investigators.”

The kit is designed for use with Spectrum CE System and Spectrum Compact CE System. Promega is the first manufacturer to develop and launch a capillary electrophoresis instrument capable of 8-dye STR analysis.

Reduced Stutter in Forensic DNA Analysis

Stutter has been a major challenge of forensic DNA analysis for decades. When DNA is amplified using Taq polymerase, the enzyme occasionally slips across repeated sequences, resulting in a new fragment that is shorter than the original. When the sample is analyzed by capillary electrophoresis, the resulting electropherogram will show an extra peak that is one repeat shorter, and sometimes one repeat longer, than the true peak. These extra peaks create challenges for analysis when a sample potentially contains DNA from multiple contributors. It is difficult to determine whether a peak represents stutter or an allele from a minor contributor.

The enzyme included in Paradyme™ 27GY STR System is engineered to minimize “slippage” during amplification of repetitive DNA sequences common in forensic DNA analysis. The enzyme reduces stutter signal intensity by an average of 8-fold relative to current systems, often rendering it undetectable from instrument baseline noise. This minimizes a significant source of uncertainty in forensic casework. As a result, labs are able to provide conclusive results for complex mixtures, generate more accurate profiles for casework and databases, and decrease their turnaround time for sample analysis.

Promega first unveiled the novel engineered enzyme at the International Symposium on Human Identification in 2024.

Advantages of Paradyme™ 27GY STR System

Paradyme™ 27GY STR System is an 8-dye multiplex that includes 23 autosomal STR loci, Amelogenin and key Y-STR loci, supporting CODIS core loci requirements and the expanded CODIS framework used by crime laboratories in the United States and internationally.

System benefits include:

  • Average of 8-fold reduction in stutter signal intensity, producing clearer profiles at amplification
  • Fewer data edits, reducing time spent on analysis
  • Reduced stutter and Y-STR loci improve NoC determination accuracy
  • Higher interpretation confidence with more complex mixtures, reducing analyst fatigue and secondary technical review effort
  • Increased minor contributor detection in mixtures
  • More loci amplified from degraded samples using shortened-amplicon 8-dye multiplex
  • Quality Indicator peaks that support more informed assessment of amplification success and sample quality troubleshooting

Promega offers extensive support to forensic organizations interested in adopting Paradyme™ 27GY STR System. Laboratories can contact a local Promega representative about in-house evaluation and comparison against current chemistry. For implementation support, Promega offers forensic experts to support on-site optimization, customized validation, and hands-on training for chemistry and instrumentation with over 200 forensic customer validation projects completed globally.

For more information about Paradyme™ 27GY STR System, visit www.promega.com/ParadymePR.

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260918993802/en/

Contacts

Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye